Advertisement

Methadone Side Effects: Constipation, Respiratory Depression, Sedation, Sleep-Disordered Breathing, and the Endocrine System

  • Lynn R. Webster
Chapter

Abstract

Methadone is an effective analgesic for the relief of moderate-to-severe pain unresponsive to non-opioid treatments [1]. However, candidates for methadone therapy must be carefully selected and closely monitored for side effects. The primary risk with methadone is death from respiratory depression, particularly when initiating therapy or changing doses, and clinicians who prescribe methadone should understand its unique pharmacologic properties. Nowhere are educated prescriber practices and precise patient adherence to medical direction more vital than in methadone therapy for chronic pain.

Keywords

Continuous Positive Airway Pressure Respiratory Depression Methadone Maintenance Treatment Sleep Study Central Sleep Apnea 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

Dr. Webster acknowledges the contribution of medical writer Beth Dove of Dove Medical Communications in Salt Lake City, Utah, in the preparation of this manuscript.

References

  1. 1.
    United States Food and Drug Administration. Public health advisory: methadone use for pain control may result in death and life-threatening changes in breathing and heart beat. Rockville, MD: United States Food and Drug Administration; 2006.Google Scholar
  2. 2.
    Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105–20.PubMedGoogle Scholar
  3. 3.
    Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74(8):1347–54.PubMedGoogle Scholar
  4. 4.
    Webster LR, Choi Y, Desai H, Grant BJB, Webster L. Sleep-disordered breathing and chronic opioid therapy. Pain Med. 2008;9(4):425–32.PubMedCrossRefGoogle Scholar
  5. 5.
    Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Fakata KL, Cole BE. Peripheral opioid antagonists: a therapeutic advance for optimizing opioid gastrointestinal tolerability. J Fam Pract. 2007;56(6 Suppl Peripheral):S3–12.PubMedGoogle Scholar
  7. 7.
    Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7(1):39–46.PubMedGoogle Scholar
  8. 8.
    Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Center for Substance Abuse Treatment. Summary report of the meeting: Methadone mortality—a reassessment. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2007.Google Scholar
  10. 10.
    Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999–2006. NCHS Data Brief. 2009;22:1–8.PubMedGoogle Scholar
  11. 11.
    United States Food and Drug Administration. Information for healthcare professionals: methadone hydrochloride. Rockville, MD: United States Food and Drug Administration; 2006.Google Scholar
  12. 12.
    GAO. (Government Accountability Office). Methadone-associated overdose deaths: factors contributing to increased deaths and efforts to prevent them. GAO-09-341. Washington, DC; March 2009.Google Scholar
  13. 13.
    Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med. 2011;12(S2):S26–35.PubMedCrossRefGoogle Scholar
  14. 14.
    The use of opioids for the treatment of chronic pain: A consensus statement from American Academy of Pain Medicine and American Pain Society. Glenview, IL, 2007. http://www.ama-­assn.org/ama1/pub/upload/mm/455/opioidschronicpain.pdf. Accessed October 28, 2011.
  15. 15.
    Santiago TV, Pugliese AC, Edelman NH. Control of breathing during methadone addiction. Am J Med. 1977;62(3):347–54.PubMedCrossRefGoogle Scholar
  16. 16.
    Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153–93.PubMedCrossRefGoogle Scholar
  17. 17.
    Bunten H, Liang WJ, Pounder D, Seneviratne C, Osselton MD. CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol. 2011;16(1):142–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Rich BA, Webster LR. A review of forensic implications of opioid prescribing with examples from malpractice cases involving opioid-related overdose. Pain Med. 2011;12(S2):S59–65.PubMedCrossRefGoogle Scholar
  19. 19.
    Webster LR. Methadone-related deaths. J Opioid Manage. 2005;1(4):211–7.Google Scholar
  20. 20.
    Toombs JD. Oral methadone dosing for chronic pain: a practitioner’s guide. Pain Treatment Topics. (http://pain-topics.org/). March 12, 2008.
  21. 21.
    Toombs JD, Kral LA. Methadone treatment for pain states. Am Fam Physician. 2005;71(7):1353–8.PubMedGoogle Scholar
  22. 22.
    Dolophine side effects and drug interactions. RxList.com. Owned and operated by WebMD. 2011. http://www.rxlist.com/dolophine-drug.htm. Accessed October 31, 2011.
  23. 23.
    Cavalieri TA. Pain management in the elderly. J Am Osteopath Assoc. 2002;102:481–5.PubMedGoogle Scholar
  24. 24.
    Six opioid safety (SOS) steps. PainSAFE. American Pain Foundation. http://PainSAFE.org. Accessed October 27, 2011.
  25. 25.
    Eight prescribing guidelines. PainSAFE. American Pain Foundation. http://PainSAFE.org. Accessed October 27, 2011.
  26. 26.
    Paulozzi LJ, Logan JE, Hall AJ, McKinstry E, Kaplan JA, Crosby AE. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction. 2009;104(9):1541–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Ersek M, Cherrier MM, Overman SS, Irving GA. The cognitive effects of opioids. Pain Manag Nurs. 2004;5(2):75–93.PubMedCrossRefGoogle Scholar
  28. 28.
    Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage. 2003;25(6):559–77. Review.PubMedCrossRefGoogle Scholar
  29. 29.
    Teichtahl H, Wang D. Sleep-disordered breathing with chronic opioid use. Expert Opin Drug Saf. 2007;6(6):641–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Walker JM, Farney RJ, Rhondeau SM, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med. 2007;3(5):455–61.PubMedGoogle Scholar
  31. 31.
    Wang D, Teichtahl H, Drummer O, et al. Central sleep apnea in stable methadone maintenance treatment patients. Chest. 2005;128:1348–56.PubMedCrossRefGoogle Scholar
  32. 32.
    Utah Department of Health. Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain. Salt Lake City, UT: Utah Department of Health; 2009.Google Scholar
  33. 33.
    Webster LR. Examining the relationship between long-term opioid therapy and sleep-­disordered breathing. Pract Pain Manage. 2008;8(9):56–62.Google Scholar
  34. 34.
    Colameco S, Coren JS. Opioid-induced endocrinopathy. J Am Osteopath Assoc. 2009;109(1):20–5.PubMedGoogle Scholar
  35. 35.
    Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9:28–36.PubMedGoogle Scholar
  36. 36.
    Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377–84.PubMedCrossRefGoogle Scholar
  37. 37.
    Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmüller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90(1):203–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009;25(2):170–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain. 2006;7(3):200–10.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.CRILifetreeSalt Lake CityUSA

Personalised recommendations